Comparing two drug combinations for newly diagnosed follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different combinations of medicines for people with a type of follicular lymphoma (grade 3A) that hasn't been treated yet. The goal is to see which combination is more effective and has manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with follicular lymphoma grade 3A that tests positive for a protein called CD20.
- You have not yet had any treatment for lymphoma.
- You have at least one sign of significant disease (like large lymph nodes or symptoms).
- You are 18 years or older.
- You are well enough to be up and about (performance status 0, 1, or 2).
- You have adequate liver, kidney, and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of three medications (acalabrutinib, lenalidomide, and rituximab) for people with a type of slow-growing lymphoma called follicular lymphoma. The goal is to see if this combination can control the disease and possibly lead to remission.
Hear when a new Follicular Lymphoma Grade 3A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.